Hormone replacement therapy in postmenopausal women: Urinary N- telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density

American Journal of Medicine

Volumn 102, Issue 1, 1997, Pages 29-37

  Chesnut III, Charles H ^a   Bell, Norman H ^b   Clark, Guy S ^c   Drinkwater, Barbara L ^d   English, Susan C ^e   Johnston Jr , C Conrad ^f   Notelovitz, Morris ^g   Rosen, Clifford ^h   Cain, Daniel F ⁱ   Flessland, Karen A ⁱ   Mallinak, Nancy J S ⁱ  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c Cancer Center of Santa Barbara   (United States)

^d Pacific Medical Centers   (United States)

^e Deaconess Research Institute   (United States)

^f INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^g Women's Medical and Diagnostic Center   (United States)

^h ST JOSEPH HOSPITAL   (United States)

ⁱ Ostex International Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; COLLAGEN TYPE 1; CONJUGATED ESTROGEN; ESTROGEN; MEDROXYPROGESTERONE ACETATE; PEPTIDE; PROGESTERONE;

ADULT; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MONITORING; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINALYSIS;

ADULT; BONE DENSITY; CALCIUM CARBONATE; COLLAGEN; COLLAGEN TYPE I; DENSITOMETRY, X-RAY; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; LINEAR MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PEPTIDES; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; PROGESTERONE;

EID: 0003062649     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(96)00387-7     Document Type: Article

References (34)

1. Riggs BL, Melton LJ. Involutional osteoporosis. NEJM. 1986;314:1676-1686.
2. Cummings SR, Black DM, Rubin SM. Lifetime risks of hip, Colles, or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med. 1989;149:2445-2448.
3. Riggs BL, Melton LJ. The prevention and treatment of osteoporosis. NEJM. 1992;327:620-627.
4. Weiss NS, Ure CL, Ballard JH, et al. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. NEJM. 1980;303: 1195-1201.
5. Ettinger B, Genant HK, Cann CE. Long-term estrogen replacement prevents bone loss and fractures. Ann Intern Med. 1985;102:319-324.
6. Keil DP, Felson DT, Anderson JJ, et al. Hip fracture and the use of estrogens in postmenopausal women: the Framingham study. NEJM. 1987;317:1169-1174.
7. Johnston CC Jr, Melton LJ III, Lindsay R, Eddy DM. Clinical indications for bone mass measurements: a report from the Scientific Advisory Board of the National Osteoporosis Foundation. J Bone Miner Res. 1989;4:1-28.
8. Chesnut CH III. Medical treatment of osteoporosis. Phys Med Rehab Clin North Am. 1995;6:639-648.
9. Hanson DA, Weis MAE, Bollen AM, et al. A specific immunoassay for monitoring bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res. 1992;7:1251-1258.
10. Garnero P, Shih W, Gineyts E, et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 1994;79:1693-1700.
11. Gertz BJ, Shao P, Hanson DA, et al. Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine. J Bone Miner Res. 1994;9:135-142.
12. Gundberg GM, Hauschka PV, Lian JB, Gallop PM. Osteocalcin: isolation, characterization and detection. Methods Enzymol. 1984; 107:517-543.
13. Farley JR, Chesnut CH, Baylink DJ. Improved method for determination of serum alkaline phosphatase of skeletal origin. Clin Chem. 1981;27:2002-2007.
14. Farley JR, Hall SL, Herring S, et al. Reference standards for quantification of skeletal alkaline phosphatase activity in serum by heat inactivation and lectin precipitation. Clin Chem. 1993;39:1878-1884.
15. Johnson J, Dawson-Hughes B. Precision and stability of dual energy x-ray absorptiometry measurements. Calcif Tissue Int. 1991;49:174-178.
16. Hanley JA, McNeil BJ. A method of comparing areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983; 148:839-843.
17. Prestwood KM, Pilbeam CC, Burleson JA, et al. The short term effects of conjugated estrogen on bone turnover in older women. J Clin Endocrinol Metab. 1994;79:366-371.
18. Marshall LA, Cain DF, Dmowski WB, Chesnut CH III. Urinary N-telopeptides to monitor bone resorption while on GnRH agonist therapy. Obstet Gynecol. 1996;87:350-354.
19. Raisz LG, Wiita B, Artis A, et al. Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J Clin Endocrinol Metab. 1996; 81:37-43.
20. Christiansen C, Lindsay R. Estrogen, bone loss and preservation. Osteoporosis Int. 1991;1:7-13.
21. Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992;117:1-9.
22. Riis B, Thomsen K, Christiansen C. Does calcium supplementation prevent postmenopausal bone loss? A double-blind, controlled clinical study. NEJM. 1987;316:173-177.
23. Elders PJM, Netelenbos JC, Lips P, et al. Calcium supplementation reduces vertebral bone loss in perimenopausal women: a controlled trial in 248 women between 46 and 55 years of age. J Clin Endocrinol Metab. 1991;73:533-540.
24. Civitelli R, Gonnelli S, Zaccheif S, et al. Bone turnover in postmenopausal osteoporosis: effect of calcitonin treatment. J Clin Invest. 1988;82:1268-1274.
25. Black DM, Cummings SR, Genant HK, et al. Axial and appendicular bone density predicts fractures in older women. J Bone Miner Res. 1992;7:633-638.
26. Ross PD, Wasnich RD, Vogel JM. Detection of prefracture spinal osteoporosis using bone mineral absorptiometry. J Bone Miner Res. 1988;3:1-11.
27. Melton LJ III, Atkinson EJ, O'Fallon WM, et al. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res. 1993;8:1227-1233.
28. Cummings SR, Black DM, Nevitt MD, et al. Bone density at various sites for prediction of hip fractures. Lancet. 1993;341:72-75.
29. Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone marrow resorption predict hip fracture in elderly women: the Epidos prospective study. J Bone Miner Res. 1996;11:1531-1538.
30. Melton LJ, Khosla S, Atkinson EJ, et al. Impact of high bone turnover on bone loss and fractures in the elderly, (abst). J Bone Miner Res. 1995;10:(suppl S1):449. Abstract.
31. Chesnut CH, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med. 1995;99:144-152.
32. Eyre DR. New biomarkers of bone resorption. J Clin Endocrinol Metab. 1992;74:470A-473C.
33. Stepan JJ, Pospichal J, Presl J, Pacovsky V. Bone loss and biochemical indices of bone remodeling in surgically postmenopausal women. Bone. 1987;8:279-284.
34. Christiansen C, Riis BJ, Rodbro P. Screening procedure for women at risk of developing postmenopausal osteoporosis. Osteoporosis Int. 1990; 1:35-40.